Gene, Cell and Tissue

Published by: Kowsar

Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes

Janella Hudson 1 , Teresita Munoz-Antonia 2 , Eric Haura 3 , 4 , Doug Cress 5 , Vani N. Simmons 1 , 4 and Gwendolyn P. Quinn 1 , 4 , *
Authors Information
1 Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
2 Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
3 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
4 Department of Oncologic Science, Morsani College of Medicine, University of South Florida, Tampa, United States
5 Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
Article information
  • Gene, Cell and Tissue: April 01, 2016, 3 (2); e35961
  • Published Online: February 14, 2016
  • Article Type: Discussion
  • Received: December 31, 2015
  • Accepted: January 11, 2016
  • DOI: 10.17795/gct-35961

To Cite: Hudson J, Munoz-Antonia T, Haura E, Cress D, Simmons V N, et al. Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes, Gene Cell Tissue. 2016 ; 3(2):e35961. doi: 10.17795/gct-35961.

Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Arguments
3. Conclusions
  • 1. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015; 65(6): 457-80[DOI][PubMed]
  • 2. Cress WD, Chiappori A, Santiago P, Munoz-Antonia T. Lung cancer mutations and use of targeted agents in Hispanics. Rev Recent Clin Trials. 2014; 9(4): 225-32[PubMed]
  • 3. McQuitty E, Zhang W, Hendrickson H, Tio FO, Jagirdar J, Olsen R, et al. Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. Arch Pathol Lab Med. 2014; 138(3): 390-4[DOI][PubMed]
  • 4. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006; 24(14): 2158-63[DOI][PubMed]
  • 5. Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL. Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer. 2015; 15(4): 248-54[DOI][PubMed]
  • 6. Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, et al. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015; 121(7): 1138-46[DOI][PubMed]
  • 7. Gefitinib (Iressa): US Food and Drug Administration. 2015;
  • 8. Erlotinib: U.S. Food and Drug Administration. 2015;
  • 9. Arrieta O, Cardona AF, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G, et al. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015; 10(5): 838-43[DOI][PubMed]
  • 10. Colby SL, Ortman JM. Projections of the Size and Composition of the US Population: 2014 to 2060. 2015;
  • 11. Vega WA, Rodriguez MA, Gruskin E. Health disparities in the Latino population. Epidemiol Rev. 2009; 31: 99-112[DOI][PubMed]
  • 12. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011; 29(15): 2121-7[DOI][PubMed]
  • 13. Okimoto RA, Bivona TG. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3): 309-21[PubMed]
  • 14. Perez-Soler R. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene. 2009; 28 Suppl 1-45[DOI][PubMed]
  • 15. Weickhardt AJ, Doebele RC, Camidge DR. A time to test, a time to treat. J Thorac Dis. 2012; 4(2): 223-5[DOI][PubMed]
  • 16. Suda K, Mitsudomi T. Racial differences in lung cancer genetics. J Thorac Oncol. 2015; 10(2): 230-1[DOI][PubMed]
  • 17. Cote ML, Haddad R, Edwards DJ, Atikukke G, Gadgeel S, Soubani AO, et al. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. J Thorac Oncol. 2011; 6(3): 627-30[DOI][PubMed]
  • 18. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2): 154-62[DOI][PubMed]
  • 19. Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 2011; 6(11): 1955-9[DOI][PubMed]
  • 20. Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? Lung Cancer. 2013; 81(3): 347-53[DOI][PubMed]
  • 21. Ibrahim SA. Equity in Lung Cancer Care and Outcomes. J Gen Intern Med. 2015; 30(10): 1385-6[DOI][PubMed]
  • 22. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013; 15(4): 415-53[DOI][PubMed]
  • 23. Lathan CS. Lung Cancer Disparities in the Era of Personalized Medicine. Am J Hematol Oncol. 2015; 11(2): 5-8
  • 24. Garcia Mosqueira A, Hua LM, Sommers BD. Racial Differences in Awareness of the Affordable Care Act and Application Assistance Among Low-Income Adults in Three Southern States. Inquiry. 2015; 52[DOI][PubMed]
  • 25. Wolfson JA, Sun CL, Wyatt LP, Hurria A, Bhatia S. Impact of care at comprehensive cancer centers on outcome: Results from a population-based study. Cancer. 2015; 121(21): 3885-93[DOI][PubMed]
  • 26. Weksler B, Kosinski AS, Burfeind WR, Silvestry SC, Sullivan J, D'Amico TA. Racial and Ethnic Differences in Lung Cancer Surgical Stage: An STS Database Study. Thorac Cardiovasc Surg. 2015; 63(7): 538-43[DOI][PubMed]
  • 27. Chen GJ, Arney J, Helm A, Braun U, Richardson P, Chen P, et al. Genomic-based targeted therapy and management of advanced non-small cell lung cancer: Protocol for a qualitative study of oncologists’ perceptions and behaviors regarding genomic-based targeted therapy. J Solid Tumors. 2015; 5(1)[DOI]
  • 28. Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J. 2012; 39(2): 366-72[DOI][PubMed]
  • 29. Mileshkin L, Shah B, Michael M. Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside? Chemother Res Pract. 2012; 2012: 838509[DOI][PubMed]
  • 30. Spicer J, Tischer B, Peters M. Lba2_Pr * Egfr Mutation Testing and Oncologist Treatment Choice in Advanced Nsclc: Global Trends and Differences. Ann Oncol. 2015; 26[DOI]
  • 31. Adamson RT. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications. Am J Manag Care. 2013; 19(19 Suppl)-404[PubMed]
  • 32. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996; 87(2): 159-70[PubMed]
  • 33. Gray SW, Hicks-Courant K, Lathan CS, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract. 2012; 8(6): 329-35[DOI][PubMed]
  • 34. Rose AL, Peters N, Shea JA, Armstrong K. Attitudes and misconceptions about predictive genetic testing for cancer risk. Community Genet. 2005; 8(3): 145-51[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments